Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 studyJonathan P. Piccini, Veronika Eder, Moritz Mirna et al.|The Lancet|2022Cited by 310
Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertensionDiana Bonderman, Iréne Lang, Walter Klepetko et al.|Thrombosis and Haemostasis|2005Cited by 296
High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertensionDiana Bonderman, Iréne Lang, Meinhard Kneußl et al.|Thrombosis and Haemostasis|2003Cited by 254
Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic DysfunctionMark C. Petrie, Eric J. Velazquez, Imtiaz S. Ali et al.|Circulation|2016Cited by 168